Actively Recruiting
Study of Early Tumor Biopsy and Blood Tests to Find Survival Mechanisms After Targeted Treatment for Advanced Lung Cancer
Led by University of Colorado, Denver · Updated on 2026-02-20
100
Participants Needed
1
Research Sites
47 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying lung cancer patients with specific genetic mutations to understand how tumor cells survive early responses to targeted treatments called Tyrosine Kinase Inhibitors TKIs. This observational study focuses on non-small cell lung cancer NSCLC at advanced stages, aiming to identify early survival mechanisms in tumors to help develop better combination therapies and improve patient outcomes. Participants will be grouped based on their treatment type those receiving targeted therapy for gene mutations like EGFR, ALK, ROS1, or BRAF, and those receiving immunotherapy or chemotherapy plus immunotherapy without these mutations. The study includes collecting tumor biopsies and blood samples at the start and after about two weeks of treatment to analyze changes in gene and protein expression. Some patients may decline biopsy and participate through blood draws only. During the study, participants will undergo tumor biopsies if possible, blood draws, and ongoing monitoring of tumor response up to three years. Researchers will assess gene and protein changes early in treatment and evaluate the depth of tumor response over time. All participants must be able to consent and meet health criteria. The study support includes careful safety monitoring, with no prior systemic therapy allowed for metastatic disease.
CONDITIONS
Brief Title
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
Research Team
B
Brandi Kubala
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here